Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CFI-400945 Monotherapy or with Azacitidine in AML, MDS, or CMML
NCT04730258Phase 2Active, not recruiting
- Sponsor
- Treadwell Therapeutics
- Start
- Apr 2021
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of ocifisertib in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML), sponsored by Treadwell Therapeutics. Started Apr 2021; status: active, not recruiting.
02
Drugs
ocifisertib
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on NCT04730258.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04730258.